Marlies Wijsenbeek1, Michael Kreuter2, Amy Olson3, Aryeh Fischer4, Elisabeth Bendstrup5, Christopher D Wells6, Christopher P Denton7, Baher Mounir8, Leila Zouad-Lejour8, Manuel Quaresma8, Vincent Cottin9. 1. Department of Respiratory Medicine, Erasmus MC, University Medical Centre , Rotterdam , The Netherlands. 2. Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research , Heidelberg , Germany. 3. National Jewish Health , Denver , CO , USA. 4. University of Colorado School of Medicine , Denver , CO , USA. 5. Department of Respiratory Diseases and Allergy, Aarhus University Hospital , Aarhus , Denmark. 6. Decision Resources Group, Burlington , MA , USA. 7. Centre for Rheumatology and Connective Tissue Diseases, University College London Division of Medicine , London , UK. 8. Boehringer Ingelheim International GmbH, Ingelheim am Rhein , Germany. 9. Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Claude Bernard University Lyon 1 , Lyon , France.
Abstract
Objective: Some patients with interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF) develop a progressive fibrosing phenotype. We investigated the diagnosis and management of non-IPF ILDs using data from a survey of physicians and from US insurance claims. Methods: Pulmonologists, rheumatologists and internists in France, Germany, Italy, Japan, Spain, UK and US who had managed ≥10 patients with non-IPF ILDs in the past year, including those with progressive fibrosing ILDs, completed an online survey. Data on US insurance and prescription claims were obtained from a repository that aggregates data on claims routed from providers or pharmacies to payers. Results: In May-June 2017, 243 pulmonologists, 203 rheumatologists and 40 internists completed an online survey. Respondents estimated that 18-32% of patients diagnosed with non-IPF ILDs develop progressive fibrosis and that time from symptom onset to death in these patients was 61-80 months. Drug treatment was given to 50-75% of patients with non-IPF progressive fibrosing ILDs. Reasons for patients not being treated included that physicians considered patients to have mild or slowly progressing disease, or did not believe that available treatments are effective or well tolerated. Corticosteroids were the preferred first-line treatment for all types of non-IPF ILD. There was considerable heterogeneity in preferences for second- and third-line treatments. US insurance claims data from 3823 patients indicated that, in 2016, 50-75% of patients with ILDs received drug treatment (mostly corticosteroids) for their ILD. Conclusions: Physicians estimate that 18-32% of patients diagnosed with non-IPF ILDs develop a progressive fibrosing phenotype and that these patients experience significant delays in the diagnosis of ILD and the detection of progressive fibrosis. Between 25% and 50% of patients with progressive fibrosing ILDs do not receive drug therapy. There is an unmet need for effective and well tolerated treatments for progressive fibrosing ILDs.
Objective: Some patients with interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF) develop a progressive fibrosing phenotype. We investigated the diagnosis and management of non-IPF ILDs using data from a survey of physicians and from US insurance claims. Methods: Pulmonologists, rheumatologists and internists in France, Germany, Italy, Japan, Spain, UK and US who had managed ≥10 patients with non-IPF ILDs in the past year, including those with progressive fibrosing ILDs, completed an online survey. Data on US insurance and prescription claims were obtained from a repository that aggregates data on claims routed from providers or pharmacies to payers. Results: In May-June 2017, 243 pulmonologists, 203 rheumatologists and 40 internists completed an online survey. Respondents estimated that 18-32% of patients diagnosed with non-IPF ILDs develop progressive fibrosis and that time from symptom onset to death in these patients was 61-80 months. Drug treatment was given to 50-75% of patients with non-IPF progressive fibrosing ILDs. Reasons for patients not being treated included that physicians considered patients to have mild or slowly progressing disease, or did not believe that available treatments are effective or well tolerated. Corticosteroids were the preferred first-line treatment for all types of non-IPF ILD. There was considerable heterogeneity in preferences for second- and third-line treatments. US insurance claims data from 3823 patients indicated that, in 2016, 50-75% of patients with ILDs received drug treatment (mostly corticosteroids) for their ILD. Conclusions: Physicians estimate that 18-32% of patients diagnosed with non-IPF ILDs develop a progressive fibrosing phenotype and that these patients experience significant delays in the diagnosis of ILD and the detection of progressive fibrosis. Between 25% and 50% of patients with progressive fibrosing ILDs do not receive drug therapy. There is an unmet need for effective and well tolerated treatments for progressive fibrosing ILDs.
Entities:
Keywords:
Disease management; drug therapy; immunosuppression; pulmonologist; rheumatologist; survey
Authors: Lorriana E Leard; Are M Holm; Maryam Valapour; Allan R Glanville; Sandeep Attawar; Meghan Aversa; Silvia V Campos; Lillian M Christon; Marcelo Cypel; Göran Dellgren; Matthew G Hartwig; Siddhartha G Kapnadak; Nicholas A Kolaitis; Robert M Kotloff; Caroline M Patterson; Oksana A Shlobin; Patrick J Smith; Amparo Solé; Melinda Solomon; David Weill; Marlies S Wijsenbeek; Brigitte W M Willemse; Selim M Arcasoy; Kathleen J Ramos Journal: J Heart Lung Transplant Date: 2021-07-24 Impact factor: 13.569
Authors: Kathleen Oare Lindell; Sara Jo Klein; Melinda S Veatch; Kevin F Gibson; Daniel J Kass; Mehdi Nouraie; Margaret Q Rosenzweig Journal: Ann Am Thorac Soc Date: 2021-11
Authors: Thomas Simpson; Shaney L Barratt; Paul Beirne; Nazia Chaudhuri; Anjali Crawshaw; Louise E Crowley; Sophie Fletcher; Michael A Gibbons; Philippa Hallchurch; Laura Horgan; Ieva Jakaityte; Thomas Lewis; Tom McLellan; Katherine J Myall; Ryan Miller; David J F Smith; Stefan Stanel; Muhunthan Thillai; Fiona Thompson; Timothy Wallis; Zhe Wu; Philip L Molyneaux; Alex G West Journal: Eur Respir J Date: 2021-07-08 Impact factor: 16.671
Authors: Anna-Maria Hoffmann-Vold; Yannick Allanore; Elisabeth Bendstrup; Cosimo Bruni; Oliver Distler; Toby M Maher; Marlies Wijsenbeek; Michael Kreuter Journal: Respir Res Date: 2020-07-23